Nifedipine: a myocardial protective agent.
The effectiveness of the calcium antagonist nifedipine in preserving postischemic myocardial function and structural integrity was experimentally demonstrated in isolated rabbit hearts, in conscious dogs subjected to myocardial infarction, in open chest anesthetized dogs with normothermic regional ischemia induced for 1 to 2 hours and in dogs undergoing hypothermic global ischemia for 2 hours followed by 2 hours of reperfusion. Nifedipine had a beneficial effect on postischemic myocardial stiffness and mitochondrial calcium accumulation, which were correlated. Administration of nifedipine at the onset of myocardial infarction increased blood flow to ischemic zones of myocardial infarction and resulted in less loss of creatine kinase. It reduced by two- to three-fold the volume of the ischemia-reperfusion injury induced by left anterior descending coronary arterial occlusion and release and preserved indexes of hemodynamic function. Nifedipine was found effective in protecting myocardial performance and structure after 2 hours of global ischemia during hypothermic cardiopulmonary bypass. It is suggested that this agent may be useful as an adjunct to cold cardioplegia in man for enhanced myocardial protection during cardiac surgery.
D000818:Animals; D002118:Calcium / Q000032:analysis; D002315:Cardiopulmonary Bypass; D003327:Coronary Disease / Q000188:drug therapy; D003402:Creatine Kinase; D004285:Dogs; D006321:Heart / Q000187:drug effects*; D006335:Heart Injuries; D008929:Mitochondria, Heart / Q000032:analysis; D009206:Myocardium / Q000201:enzymology; D009543:Nifedipine / Q000494:pharmacology*; D010477:Perfusion; D011725:Pyridines / Q000494:pharmacology*; D011817:Rabbits; D012039:Regional Blood Flow / Q000187:drug effects
D011725:Pyridines; D003402:Creatine Kinase; D009543:Nifedipine; D002118:Calcium